Bernstein analyst Lance Wilkes maintains $Elevance Health (ELV.US)$ with a buy rating, and adjusts the target price from $629 to $549.
According to TipRanks data, the analyst has a success rate of 65.3% and a total average return of 11.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Elevance Health (ELV.US)$'s main analysts recently are as follows:
The firm has revised its model and valuation for Elevance Health, taking into account the third-quarter outcomes and fresh insights from management regarding the financial outlook for the next two years.
After a tumultuous initial week of Q3 earnings characterized by significant medical loss ratio misses and unforeseen negative outlooks, the evaluation of the resets and implications stemming from the earnings reports of UnitedHealth and Elevance Health has been conducted.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.